<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167257</url>
  </required_header>
  <id_info>
    <org_study_id>TCGHUROL001</org_study_id>
    <nct_id>NCT01167257</nct_id>
  </id_info>
  <brief_title>Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome</brief_title>
  <official_title>Comparative Study of the Efficacy and Safety of Liposome Encapsulated Botulinum Toxin-A (Lipotoxin) Versus Normal Saline Instillation in Treatment of Patients With Refractory Overactive Bladder Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Buddhist Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overactive bladder (OAB) is a bothered symptom syndrome. Traditional medication for OAB is
      antimuscarinic agent. However, adverse events such as dry mouth, constipation, blurred
      vision, and dizziness may prohibit patient to take this drug for OAB. Intravesical botulinum
      toxin A (BoNT-A) is a novel treatment however, BoNT-A can cause acute urinary retention and
      large postvoid residual. In this grant we will evaluate liquid liposome delivery of BoNT-A
      (Liposome encapsulated BoNT-A) into the bladder without the need for cystoscopic-guided
      needle injection for refractory OAB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overactive bladder (OAB) is a symptom syndrome characterized by urgency frequency with or
      without urgency incontinence, usually no metabolic or anatomical disorders can be found and
      it may have great impact on quality of life. Traditional medication for OAB is antimuscarinic
      agent which targets at the muscarinic receptors. There are several adverse events such as dry
      mouth, constipation, blurred vision, and dizziness related to antimuscarinics, therefore,
      some patients cannot tolerated this treatment. Intravesical botulinum toxin A (BoNT-A) has
      recently emerged as novel treatment for OAB refractory to antimuscarinics, however, BoNT-A
      injection can cause acute urinary retention and large postvoid residual. Urinary tract
      infection usually occurred following large postvoid residual and urinary retention. If we can
      deliver BoNT-A through the urothelium to the suburothelial space, but not into the detrusor
      layer, we might have therapeutic effects on the urothelial sensory nerves without
      compromising the detrusor contractility. This treatment will enable us to prevent the
      undesired detrusor underactivity after BoNT-A injection, especially in the elderly patients
      who had impaired detrusor contractility and OAB. Liposomes are vesicles, composed of
      concentric phospholipid bilayers separated by aqueous compartments. Because liposomes adsorb
      to cell surfaces and fuse with cells, they are being used as vehicles for drug delivery and
      gene therapy. In this grant we will evaluate liquid liposome delivery of BoNT-A (Liposome
      encapsulated BoNT-A) into the bladder without the need for cystoscopic-guided needle
      injection for refractory OAB, and study the mechanism of action of intravesical liposomal
      drug delivery. If successful, we will leverage our technology transfer expertise and bring
      the science from the bench top to the bed side to apply for a physician sponsored
      Investigational New Drug (IND) trial using liposome-BoNT in patients with OAB or DO.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change of the Total Frequency Per 3 Days</measure>
    <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
    <description>Efficacy:
Mean change of the total frequency per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.
Change = Week 4 minus Baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change of the Urgency Episodes Per 3 Days</measure>
    <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
    <description>Efficacy:
Mean change of the Urgency episodes per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.
Change = Week 4 minus Baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of the Urgency Urinary Incontinence (UUI) Per 3 Days</measure>
    <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
    <description>Efficacy:
Mean change of the urgency urinary incontinence (UUI) per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.
Change = Week 4 minus Baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Change of the Overactive Bladder Symptom Score (OABSS)</measure>
    <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
    <description>Efficacy:(measured the net change of variables from baseline to 1 month) Overactive bladder symptom score (OABSS) The OABSS is a 4-item questionnaire developed to evaluate OAB symptoms. The maximal scores are 2, 3, 5 and 5 for daytime frequency, nighttime frequency, urgency and urgency in continence, respectively.
The OABSS range = 0 to 15 ((asymptomatic to very symptomatic). Change = Week 4 minus Baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Change of the Functional Bladder Capacity (FBC)</measure>
    <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
    <description>Efficacy:(measured the net change of variables from baseline and 1 month) Functional bladder capacity (FBC) Change = Week 4 minus Baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Change of the Maximum Flow Rate (Qmax)</measure>
    <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
    <description>Efficacy:(measured the net change of variables from baseline and 1 month) Maximum flow rate (Qmax) Change = Week 4 minus Baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Change of the Postvoid Residual Volume (PVR)</measure>
    <time_frame>Baseline and 1 month after initial treatment</time_frame>
    <description>Efficacy:(measured the net change of variables from baseline and 1 month) Postvoid residual volume (PVR) Change = Week 4 minus Baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Change of the Urgency Severity Score (USS) Within 3 Days</measure>
    <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
    <description>Efficacy:(measured the net change of variables from baseline and 1 month) Urgency severity score (USS) within 3 days. The USS have 1-point scale ranging from 0 to 4. The USS grades urgency per toilet void as none, mild, moderate or severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Change of the Global Response Assessment (GRA)</measure>
    <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
    <description>Efficacy:(measured the net change of variables from baseline and 1 month) The Global response assessment (GRA) have seven point scale is centered at zero (no change): markedly worse; moderately worse; slightly worse; no change; slightly improved; moderately improved; and markedly improved.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation'</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposome encapsulated botulinum toxin A</intervention_name>
    <description>Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>Lipotoxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline instillation</intervention_name>
    <description>Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation</description>
    <arm_group_label>Control arm</arm_group_label>
    <other_name>N/S</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults with age of 20 years old or above

          2. Patients with symptoms of urgency frequency and/or urge incontinence and a urgency
             severity scale (USS) of at least 2, with or without urodynamically proven detrusor
             overactivity (DO) (defined by the International Continence Society (ICS)
             recommendation as: spontaneous detrusor contraction occurring during bladder filling
             phase or occurring before uninhibited detrusor contraction voiding at bladder capacity
             in the urodynamic study)

          3. Free of active urinary tract infection

          4. Free of bladder outlet obstruction on enrollment

          5. Free of overt neurogenic bladder dysfunction

          6. Having been treated with antimuscarinic agents for at least 4 weeks without effect or
             with intolerable adverse effects

          7. Patient has not been treated with bladder surgery for OAB, such as enterocystoplasty,
             that might affect the therapeutic effect of test drug

          8. Patient can record voiding diary for the urinary frequency and urgency

          9. Patient or his/her legally acceptable representative has signed the written informed
             consent form

        Exclusion Criteria:

          1. Use of antimuscarinic agent and effective in treatment of lower urinary tract symptoms

          2. Patients with severe cardiopulmonary disease and such as congestive heart failure,
             arrhythmia, poorly controlled hypertension, not able to receive regular follow-up

          3. Patients with bladder outlet obstruction on enrollment

          4. Patients with postvoid residual &gt;150 mL

          5. Patients with uncontrolled confirmed diagnosis of acute urinary tract infection

          6. Patients have laboratory abnormalities at screening including:

             Alanine aminotransferase (ALT) &gt;3 x upper limit of normal range Aspartate
             aminotransferase (AST) &gt;3 x upper limit of normal range Patients have abnormal serum
             creatinine level &gt;2 x upper limit of normal range

          7. Patients with any contraindication to be urethral catheterization during treatment

          8. Female patients who is pregnant, lactating, or with child-bearing potential without
             contraception.

          9. Myasthenia gravis, Eaton Lambert syndrome.

         10. Patients with any other serious disease considered by the investigator not suitable
             for general anesthesia or in the condition to enter the trial

         11. Patients participated investigational drug trial within 1 month before entering this
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hann-Chorng Kuo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yao-Chi Chuang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>July 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <results_first_submitted>September 10, 2014</results_first_submitted>
  <results_first_submitted_qc>September 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2014</results_first_posted>
  <last_update_submitted>September 19, 2014</last_update_submitted>
  <last_update_submitted_qc>September 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Buddhist Tzu Chi General Hospital</investigator_affiliation>
    <investigator_full_name>Hann-Chorng Kuo</investigator_full_name>
    <investigator_title>Department of Urology</investigator_title>
  </responsible_party>
  <keyword>Overactive bladder</keyword>
  <keyword>Detrusor overactivity</keyword>
  <keyword>Liposome</keyword>
  <keyword>Botulinum toxin A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Arm</title>
          <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>Normal saline 50ml in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50ml in single intravesical instillation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Arm</title>
          <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80mg/40ml) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50ml in single intravesical instillation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.43" spread="12.49" lower_limit="48" upper_limit="82"/>
                    <measurement group_id="B2" value="65.81" spread="14.48" lower_limit="38" upper_limit="73"/>
                    <measurement group_id="B3" value="65.12" spread="13.49" lower_limit="38" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Associated medical conditions</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Background or Prior disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Any prior disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior therapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Prior therapy taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change of the Total Frequency Per 3 Days</title>
        <description>Efficacy:
Mean change of the total frequency per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.
Change = Week 4 minus Baseline value</description>
        <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
        <population>Control arm: subject number S025 was removed from analysis for not meeting the requirement for analysis, thus control arm 27 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of the Total Frequency Per 3 Days</title>
          <description>Efficacy:
Mean change of the total frequency per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.
Change = Week 4 minus Baseline value</description>
          <population>Control arm: subject number S025 was removed from analysis for not meeting the requirement for analysis, thus control arm 27 subjects</population>
          <units>Frequency per 3 days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.64" lower_limit="-7.46" upper_limit="-1.82"/>
                    <measurement group_id="O2" value="-0.19" lower_limit="-2.98" upper_limit="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of the Urgency Episodes Per 3 Days</title>
        <description>Efficacy:
Mean change of the Urgency episodes per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.
Change = Week 4 minus Baseline value</description>
        <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
        <population>Control arm: subject number S025 was removed from analysis for not meeting the requirement for analysis, thus control arm 27 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50ml in single intravesical instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of the Urgency Episodes Per 3 Days</title>
          <description>Efficacy:
Mean change of the Urgency episodes per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.
Change = Week 4 minus Baseline value</description>
          <population>Control arm: subject number S025 was removed from analysis for not meeting the requirement for analysis, thus control arm 27 subjects</population>
          <units>Frequency per 3 days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.43" lower_limit="-11.68" upper_limit="-3.18"/>
                    <measurement group_id="O2" value="-3.43" lower_limit="-7.30" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of the Urgency Urinary Incontinence (UUI) Per 3 Days</title>
        <description>Efficacy:
Mean change of the urgency urinary incontinence (UUI) per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.
Change = Week 4 minus Baseline value</description>
        <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
        <population>Control arm: subject number S025 was removed from analysis for not meeting the requirement for analysis, thus control arm 27 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50ml in single intravesical instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of the Urgency Urinary Incontinence (UUI) Per 3 Days</title>
          <description>Efficacy:
Mean change of the urgency urinary incontinence (UUI) per 3 days from baseline to 4 weeks after the treatment day based on the 3-day voiding diary.
Change = Week 4 minus Baseline value</description>
          <population>Control arm: subject number S025 was removed from analysis for not meeting the requirement for analysis, thus control arm 27 subjects</population>
          <units>Frequency per 3 days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="-3.33" upper_limit="4.19"/>
                    <measurement group_id="O2" value="0.56" lower_limit="-1.27" upper_limit="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Change of the Overactive Bladder Symptom Score (OABSS)</title>
        <description>Efficacy:(measured the net change of variables from baseline to 1 month) Overactive bladder symptom score (OABSS) The OABSS is a 4-item questionnaire developed to evaluate OAB symptoms. The maximal scores are 2, 3, 5 and 5 for daytime frequency, nighttime frequency, urgency and urgency in continence, respectively.
The OABSS range = 0 to 15 ((asymptomatic to very symptomatic). Change = Week 4 minus Baseline value</description>
        <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10ml in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Net Change of the Overactive Bladder Symptom Score (OABSS)</title>
          <description>Efficacy:(measured the net change of variables from baseline to 1 month) Overactive bladder symptom score (OABSS) The OABSS is a 4-item questionnaire developed to evaluate OAB symptoms. The maximal scores are 2, 3, 5 and 5 for daytime frequency, nighttime frequency, urgency and urgency in continence, respectively.
The OABSS range = 0 to 15 ((asymptomatic to very symptomatic). Change = Week 4 minus Baseline value</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" lower_limit="-2.96" upper_limit="-0.76"/>
                    <measurement group_id="O2" value="-0.75" lower_limit="-2.01" upper_limit="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Change of the Functional Bladder Capacity (FBC)</title>
        <description>Efficacy:(measured the net change of variables from baseline and 1 month) Functional bladder capacity (FBC) Change = Week 4 minus Baseline value</description>
        <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
        <population>Control arm: subject number S025 was removed from analysis for not meeting the requirement for analysis, thus control arm 27 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Net Change of the Functional Bladder Capacity (FBC)</title>
          <description>Efficacy:(measured the net change of variables from baseline and 1 month) Functional bladder capacity (FBC) Change = Week 4 minus Baseline value</description>
          <population>Control arm: subject number S025 was removed from analysis for not meeting the requirement for analysis, thus control arm 27 subjects</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.86" lower_limit="-45.79" upper_limit="20.08"/>
                    <measurement group_id="O2" value="18.15" lower_limit="-16.37" upper_limit="52.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Change of the Maximum Flow Rate (Qmax)</title>
        <description>Efficacy:(measured the net change of variables from baseline and 1 month) Maximum flow rate (Qmax) Change = Week 4 minus Baseline value</description>
        <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
        <population>Control arm: subject number S025 was removed from analysis for not meeting the requirement for analysis, thus control arm 27 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 Ll water) in single intravesical instillation, one time treatment at the treatment day</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Net Change of the Maximum Flow Rate (Qmax)</title>
          <description>Efficacy:(measured the net change of variables from baseline and 1 month) Maximum flow rate (Qmax) Change = Week 4 minus Baseline value</description>
          <population>Control arm: subject number S025 was removed from analysis for not meeting the requirement for analysis, thus control arm 27 subjects</population>
          <units>mL/s</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="-2.02" upper_limit="2.25"/>
                    <measurement group_id="O2" value="-0.84" lower_limit="-4.30" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Change of the Postvoid Residual Volume (PVR)</title>
        <description>Efficacy:(measured the net change of variables from baseline and 1 month) Postvoid residual volume (PVR) Change = Week 4 minus Baseline value</description>
        <time_frame>Baseline and 1 month after initial treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Net Change of the Postvoid Residual Volume (PVR)</title>
          <description>Efficacy:(measured the net change of variables from baseline and 1 month) Postvoid residual volume (PVR) Change = Week 4 minus Baseline value</description>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" lower_limit="-20.13" upper_limit="14.84"/>
                    <measurement group_id="O2" value="-2.31" lower_limit="-19.43" upper_limit="14.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Change of the Urgency Severity Score (USS) Within 3 Days</title>
        <description>Efficacy:(measured the net change of variables from baseline and 1 month) Urgency severity score (USS) within 3 days. The USS have 1-point scale ranging from 0 to 4. The USS grades urgency per toilet void as none, mild, moderate or severe.</description>
        <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50ml in single intravesical instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Net Change of the Urgency Severity Score (USS) Within 3 Days</title>
          <description>Efficacy:(measured the net change of variables from baseline and 1 month) Urgency severity score (USS) within 3 days. The USS have 1-point scale ranging from 0 to 4. The USS grades urgency per toilet void as none, mild, moderate or severe.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Change of the Global Response Assessment (GRA)</title>
        <description>Efficacy:(measured the net change of variables from baseline and 1 month) The Global response assessment (GRA) have seven point scale is centered at zero (no change): markedly worse; moderately worse; slightly worse; no change; slightly improved; moderately improved; and markedly improved.</description>
        <time_frame>Baseline to 4 weeks after initial treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation: Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Net Change of the Global Response Assessment (GRA)</title>
          <description>Efficacy:(measured the net change of variables from baseline and 1 month) The Global response assessment (GRA) have seven point scale is centered at zero (no change): markedly worse; moderately worse; slightly worse; no change; slightly improved; moderately improved; and markedly improved.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental Arm</title>
          <description>Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
Liposome encapsulated botulinum toxin A'
Liposome encapsulated botulinum toxin A: Liposome encapsulated BoNT-A (mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>Normal saline 50 mL in single intravesical instillation
Normal saline instillation'
Normal saline instillation: Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Right Knee osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>C-spine whiplash injury with radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Unspecified otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Foreign body in conjunctival SAC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal fullness pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Functional disorder of stomach disturbance irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness and giddiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oral ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spondylosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fracture of ankle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Traumatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fracture of clavicle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory infection upper tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Couch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Unspecified local infections of skin and subcutaneous tissue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <description>Contusion of face, scalp, neck except eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dermatophytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hann-Chorng Kuo</name_or_title>
      <organization>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University</organization>
      <phone>886-3-8561825 ext 2113</phone>
      <email>hck@tzuchi.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

